Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

Cancer biomarkers: an emerging means of detecting, diagnosing and treating cancer.

Srivastava S.

Cancer Biomark. 2005;1(1):1-2. No abstract available.

PMID:
17192027
2.

Cancer biomarkers: an emerging means of detecting, diagnosing and treating cancer.

Srivastava S.

Dis Markers. 2005;21(1):1-2. No abstract available.

3.

[Molecular markers having a prognostic or therapeutic value in cancer].

Brousset P.

Ann Pathol. 2008 Nov;28 Spec No 1(1):S69-70. doi: 10.1016/j.annpat.2008.09.021. Epub 2008 Oct 15. French. No abstract available.

PMID:
18984307
4.

Cancer biomarkers: easier said than done.

Pritzker KP.

Clin Chem. 2002 Aug;48(8):1147-50.

5.

Molecular cancer diagnostics.

Marte B, Eccleston A, Nath D.

Nature. 2008 Apr 3;452(7187):547. doi: 10.1038/452547a. No abstract available.

PMID:
18385727
6.

Standards for validation of cancer biomarkers.

O'Connell CD, Atha DH, Jakupciak JP.

Cancer Biomark. 2005;1(4-5):233-9. Review.

PMID:
17192047
7.

Strategies for discovering novel cancer biomarkers through utilization of emerging technologies.

Kulasingam V, Diamandis EP.

Nat Clin Pract Oncol. 2008 Oct;5(10):588-99. doi: 10.1038/ncponc1187. Epub 2008 Aug 12. Review.

PMID:
18695711
8.

The cancer biomarker problem.

Sawyers CL.

Nature. 2008 Apr 3;452(7187):548-52. doi: 10.1038/nature06913. Review.

PMID:
18385728
9.

A truth serum for cancer--microRNAs have major potential as cancer biomarkers.

Chin LJ, Slack FJ.

Cell Res. 2008 Oct;18(10):983-4. doi: 10.1038/cr.2008.290. No abstract available.

PMID:
18833286
10.

Molecular diagnostics: impact upon cancer detection.

Keesee SK.

Expert Rev Mol Diagn. 2002 Mar;2(2):91-2. No abstract available.

PMID:
11962339
11.

Thymidine kinase: diagnostic and prognostic potential.

O'Neill KL, Buckwalter MR, Murray BK.

Expert Rev Mol Diagn. 2001 Nov;1(4):428-33. Review.

PMID:
11901857
12.

Personalized cancer diagnostics and therapeutics.

Roukos DH.

Expert Rev Mol Diagn. 2009 Apr;9(3):227-9. doi: 10.1586/erm.09.6. No abstract available.

PMID:
19379081
13.

Beyond PSA: utility of novel tumor markers in the setting of elevated PSA.

Lin DW.

Urol Oncol. 2009 May-Jun;27(3):315-21. doi: 10.1016/j.urolonc.2009.01.026. Review.

PMID:
19414121
14.

Circulating tumor cells: the Grand Challenge.

den Toonder J.

Lab Chip. 2011 Feb 7;11(3):375-7. doi: 10.1039/c0lc90100h. Epub 2011 Jan 5. No abstract available.

PMID:
21206959
15.

MicroRNAs as promising biomarkers for diagnosing human cancer.

Huang Y, Yang S, Zhang J, Tan L, Jiang F, Li N, Cheng J, Lu Y, Dai Y.

Cancer Invest. 2010 Jul;28(6):670-1. doi: 10.3109/07357901003631064. No abstract available.

PMID:
20210518
16.

Molecular diagnostics for monitoring and predicting therapeutic effect in cancer.

Cho WC.

Expert Rev Mol Diagn. 2011 Jan;11(1):9-12. doi: 10.1586/erm.10.111. No abstract available.

PMID:
21171915
17.

The emergent role of microRNAs in molecular diagnostics of cancer.

Tam W.

J Mol Diagn. 2008 Sep;10(5):411-4. doi: 10.2353/jmoldx.2008.080067. Epub 2008 Aug 7. No abstract available.

18.

Gene discovery in cervical cancer : towards diagnostic and therapeutic biomarkers.

Martin CM, Kehoe L, Spillane CO, O'Leary JJ.

Mol Diagn Ther. 2007;11(5):277-90. Review. Erratum in: Mol Diagn Ther. 2007;11(6):411.

PMID:
17963416
19.

Bladder cancer biomarkers: current developments and future implementation.

Alvarez A, Lokeshwar VB.

Curr Opin Urol. 2007 Sep;17(5):341-6. Review.

PMID:
17762628
20.

Biochemical and immunologic diagnosis of cancer. General cancer tests.

Laurence DJ.

Tumour Biol. 1987;8(2-3):75-7. Review. No abstract available.

PMID:
3329403
Items per page

Supplemental Content

Write to the Help Desk